CAM2029 (octreotide subcutaneous depot), SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Somatuline Autogel 120 mg, solution for injection in a pre-filled syringe
HS-19-657
Phase 3 small_molecule active
Quick answer
CAM2029 (octreotide subcutaneous depot), SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Somatuline Autogel 120 mg, solution for injection in a pre-filled syringe for gastroenteropancreatic neuroendocrine tumors is a Phase 3 program (small_molecule) at Camurus AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Camurus AB
- Indication
- gastroenteropancreatic neuroendocrine tumors
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active